Neurolixis SAS
1 clinical trials · Sponsor
| Record | Firm | Date |
|---|---|---|
| Study to Assess the Safety, Tolerability and Preliminary Efficacy of NLX-112 Versus Placebo in L-dopa-induced Dyskinesia (NCT05148884) | Neurolixis SAS | 2021-11-09 |
Track Neurolixis SAS automatically
Every clearance here is in the API, with alerts when new ones post.